Cargando…

Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients

INTRODUCTION: Three-dose mRNA vaccination against COVID-19 is unable to elicit a sufficient immune response in immunocompromised subjects. METHODS: The aim of the study was to conduct a retrospective evaluation of the efficacy of a heterologous mRNA booster with mRNA-1273 in constantly seronegative...

Descripción completa

Detalles Bibliográficos
Autores principales: Tylicki, Leszek, Biedunkiewicz, Bogdan, Ślizień, Zuzanna, Muchlado, Marta, Dębska-Ślizień, Alicja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266872/
https://www.ncbi.nlm.nih.gov/pubmed/35832697
http://dx.doi.org/10.5114/aoms/150000
Descripción
Sumario:INTRODUCTION: Three-dose mRNA vaccination against COVID-19 is unable to elicit a sufficient immune response in immunocompromised subjects. METHODS: The aim of the study was to conduct a retrospective evaluation of the efficacy of a heterologous mRNA booster with mRNA-1273 in constantly seronegative kidney transplant recipients (KTRs) after three doses of the BNT162b2 mRNA vaccine. Twelve seronegative KTRs received a mRNA-1273 booster 5 months after the third dose of BNT162b2. RESULTS: A total of 5 out of 12 patients (41.7%) seroconverted, with a mean titer of 353 BAU/ml. CONCLUSIONS: The administration of a heterologous mRNA vaccine as a booster may be an effective alternative for achieving post-vaccination immunity in seronegative KTRs.